FREDERICK, Md., June 12, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today is proud to announce it has been honored with the prestigious "Disinfection and Decontamination Products Company of the Year 2025" award by MedTech Outlook. This recognition highlights TOMI’s unwavering commitment to excellence and the strong confidence customers and industry peers have in its SteraMist iHP technolog ...

FREDERICK, Md., June 05, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® ("TOMI") (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced the appointment of Mr. David Vanston as Chief Financial Officer, effective May 30, 2025. Mr. Vanston brings more than 25 years of international financial leadership experience across the life sciences, manufacturing, and technology sectors. He has held senior finance roles at both private equity-backed and ...

TOMI Environmental Solutions (TOMZ) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Rosalyn Christian - Account ManagerHalden Shane - Chairman & CEOElissa Shane - COO & Director Conference Call Participants None - Analyst Operator Greetings. Welcome to the TOMI Environmental Solutions Inc. First Quarter two thousand twenty five Financial Results Conference Call. Please note this conference is being recorded. I will now turn the conference over to your host, Rosalynn Christian from IMS In ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased to $1,577,000, up from $1,114,000 in Q1 2024, representing a 42% increase driven by heightened demand for bit solutions and mobile systems [11] - Product-based revenues totaled $1,000,000 in Q1 2025, reflecting a 35% growth compared to Q1 2024 [11] - Service revenues generated $577,000, a 56% increase from the same prior year period [11] - BIT solution sales reached approximately $300,000, marking nearly a 200% increase from just over $100,000 in Q1 2024 [12] - Operating loss for the quarter was approximately $754,000, an improvement from the operating loss of $1,226,000 in the same quarter last year [12] - Net loss was approximately $256,000 or $0.01 per share compared to $1,310,000 or 7% loss per share in the prior year [12] - Cash and cash equivalents stood at approximately $674,000, with working capital of $3,800,000 [13] Business Line Data and Key Metrics Changes - Total sales in February 2025 saw a 42% increase compared to February 2024, with a 21% increase in April 2025 compared to April 2024 [6] - Year-to-date, there was a 169% surge in bit solution sales compared to the same period last year [6] - The company welcomed several new customers, including a division of the US Army and a children's hospital, indicating expansion in various sectors [8] Market Data and Key Metrics Changes - The company reported an increase in open sales log from approximately $877,000 at the end of 2024 to $1,600,000 by the end of Q1 2025 [10] - The IHP corporate service deployment pipeline currently stands at $1,000,000 in open proposals for 2025 [22] Company Strategy and Development Direction - The company is focused on expanding its product line and distribution strategy, with new service offerings launched in 2024 [5] - There is a commitment to educating the market on the importance of protective disinfection through the SteraMist Pro certified program [7] - The company aims to enhance its sales infrastructure by establishing new distribution channels and recruiting qualified business developers [21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about sustaining sales momentum and anticipated a positive trend in sales throughout the year [14] - The company is encouraged by significant progress made in Q1 2025, showcasing the effectiveness of its strategies and product offerings [23] - Management noted that they are not experiencing significant problems due to government budget cuts and expect increased demand from government sectors [28] Other Important Information - The company is actively seeking strong global partners and is focused on rebuilding brand presence in various international markets [21] - The partnership with AlgaFeed has opened a new aquaculture market for SteriMist IHP [8] Q&A Session Summary Question: Do you have any financial goals for the year 2025? - Management is confident that 2025 will be a great year and expects to improve on last year's numbers [25] Question: Do you anticipate any effects from the tariffs trade policy? - Management indicated that they have had minor issues with tariffs but are not experiencing significant problems with international sales [26][27] Question: Do you anticipate significant problems due to government budget cuts? - Management believes there will be an increase in demand from government sectors that utilize their products [28] Question: Any new developments on food safety? - Management reported a surge in interest and requests related to food safety, indicating a growing market [30] Question: Any updates on SteraMist for prevention of bird flu transmission? - Management noted that there is increased interest in using their products for bird flu disinfection, but no significant developments have materialized recently [31][32] Question: Any new developments on Ceramist as an ethylene oxide replacement? - Management confirmed ongoing negotiations with companies looking to replace ethylene oxide with Ceramist [33] Question: Was the order for treating pacemakers used in replacement of ethylene oxide? - The order was not a replacement but helped develop a new protocol for the medical device manufacturer [34][35] Question: Have any new ways been developed to educate the market? - The SteraMist Pro certified program was launched to educate the market and improve product usage [37][38]

Financial Performance - For the year ended December 31, 2024, total net sales increased by 5% to $7,739,000 compared to $7,355,000 in 2023[8] - Non-GAAP gross sales for the year were $7,966,000, reflecting a 6% increase from $7,483,000 in the previous year[8] - GAAP net loss for the year was $(4,477,000) or $(0.22) per share, compared to $(3,403,000) or $(0.17) per share in 2023[8] - SteraMist product-based revenues increased to $6,035,000 for the year, up from $5,781,000 in 2023, driven by higher demand for mobile and SIS units[8] - Net sales for the year ended December 31, 2024 were $7,738,842, an increase of 5.2% compared to $7,354,564 in 2023[30] - Gross profit for the year ended December 31, 2024 was $3,557,078, down 17.1% from $4,289,536 in 2023[30] - The net loss for the year ended December 31, 2024 was $4,476,762, compared to a net loss of $3,402,592 in 2023, representing an increase in loss of 31.6%[30] - Non-GAAP gross profit for the year ended December 31, 2024 was $4,789,078, an increase of 8.4% from $4,417,926 in 2023[31] - Non-GAAP net loss for the year ended December 31, 2024 was $2,049,912, compared to $2,838,399 in 2023, indicating a decrease in loss of 28%[31] Revenue Growth - International revenue grew by 33% for the year, supported by new customers in Canada, South Africa, and India[8] - Preliminary Q1 2025 revenues are expected to be approximately $1,577,000, a 42% increase from $1,114,000 in Q1 2024[19] - Sales backlog increased to $1,232,000 as of March 31, 2025, representing a 40% increase from December 31, 2024[19] Operational Metrics - The gross margin for the year was 46%, down from 58% in the prior year, while non-GAAP gross margin was 60%, up from 59%[8] - Operating expenses increased to $7,661,838 for the year ended December 31, 2024, compared to $7,638,813 in 2023, reflecting a slight increase of 0.3%[31] Assets and Liabilities - Total assets decreased from $13,357,614 in December 31, 2023 to $9,693,738 in December 31, 2024, a decline of approximately 27.5%[24] - Total liabilities increased from $4,998,720 in December 31, 2023 to $5,594,799 in December 31, 2024, an increase of approximately 11.9%[28] - Cash and cash equivalents decreased significantly from $2,339,059 in December 31, 2023 to $664,879 in December 31, 2024, a decline of about 71.6%[24] - Total shareholders' equity decreased from $8,358,894 in December 31, 2023 to $4,098,939 in December 31, 2024, a decline of approximately 51%[28] Future Outlook - The company anticipates continued improvement in 2025, driven by a strong pipeline and high-margin solution sales[9] - The company expanded partnerships with six new partners across various regions, enhancing its global distribution capabilities[8]

Financial Performance - For Q1 2025, TOMI Environmental Solutions reported net sales of $1,576,558, a 41.6% increase from $1,114,087 in Q1 2024[18]. - Gross profit for Q1 2025 was $951,745, compared to $670,668 in Q1 2024, reflecting a gross margin improvement[18]. - The net loss for Q1 2025 was $255,593, significantly improved from a net loss of $1,310,190 in Q1 2024[18]. - The basic net loss per share for the three months ended March 31, 2025, was $(0.01), compared to $(0.07) for the same period in 2024, showing a reduction in loss per share[54]. - Cash used in operations decreased to approximately $276,000 in Q1 2025 from $1,178,000 in Q1 2024[76]. - Net loss for Q1 2025 was $255,000, significantly improved from a net loss of $1,310,000 in Q1 2024, indicating better financial performance[198]. Revenue Growth - For the three months ended March 31, 2025, total revenue was $1,577,000, a 41.6% increase from $1,114,000 in the same period of 2024[60]. - SteraMist product revenue increased to $1,000,000 in Q1 2025 from $743,000 in Q1 2024, representing a 34.6% growth[60]. - Service and training revenue rose to $577,000 in Q1 2025, up 55.7% from $371,000 in Q1 2024[60]. - The United States contributed $1,192,000 to total revenue in Q1 2025, compared to $662,000 in Q1 2024, marking an increase of 80.0%[61]. - Domestic revenue grew by 80% in Q1 2025 compared to the same period last year, reflecting higher demand for solutions and services[131]. Cost Management - Operating expenses decreased to $1,706,210 in Q1 2025 from $1,897,144 in Q1 2024, a reduction of approximately 10.1%[18]. - Operating expenses decreased by $191,000, or 10%, in Q1 2025 compared to Q1 2024, primarily due to lower selling and administrative expenses[133]. - Research and development expenses for Q1 2025 were approximately $45,000, down from $68,000 in Q1 2024, a reduction of 33.8%[74]. - Selling expenses decreased to approximately $246,000 for the three months ended March 31, 2025, compared to $289,000 in 2024, representing a decline of approximately $43,000 or 15%[212]. Asset Management - Total current assets increased to $6,779,492 as of March 31, 2025, up from $6,493,113 at the end of 2024, representing a growth of 4.4%[15]. - Total assets reached $9,957,777 as of March 31, 2025, compared to $9,693,738 at the end of 2024, indicating a 2.7% increase[16]. - Cash and cash equivalents at the end of Q1 2025 were $674,181, a slight increase from $664,879 at the end of 2024[21]. - Accounts receivable increased by $112,666 in Q1 2025, while inventory saw a positive change with an increase of $158,095[21]. Inventory and Liabilities - Total inventories decreased to $3,406,000 as of March 31, 2025, from $3,578,000 at the end of 2024, a decline of 4.8%[80]. - The reserve for obsolete inventory remained stable at $1,100,000 as of both March 31, 2025, and December 31, 2024, suggesting consistent inventory management practices[40]. - As of March 31, 2025, one vendor accounted for approximately 49% of accounts payable, down from 60% as of December 31, 2024, indicating improved supplier diversification[45]. Strategic Initiatives - TOMI's Binary Ionization Technology® (BIT™) continues to be a key focus, with products actively used for COVID-19 decontamination[24]. - A significant contract for a SteraMist iHP Custom Engineered System valued at approximately $450,000 was secured with a leading university in March 2025[139]. - The deployment of SteraMist iHP technology at NASA Johnson Space Center marks an expansion into the aerospace sector[140]. - An OEM partnership with Pharma Biotech System Components LLC was announced, enhancing the SteraMist Integrated System product[142]. Market Opportunities - The global pharmaceutical market is projected to grow steadily, increasing the demand for decontamination solutions that deliver consistent fast results[161]. - The life sciences sector has adopted SteraMist iHP, enhancing efficiency and safety in operations, with Fortune 100 companies among its customers[159]. - The food safety segment presents significant growth opportunities, with increasing demand for effective sanitation solutions due to food contamination concerns[164]. - Approximately 7-10% of patients in healthcare facilities acquire healthcare-associated infections (HAIs), highlighting the need for effective disinfection measures[175]. Compliance and Recognition - The company achieved compliance and recognition from Avetta, enhancing its commitment to health, safety, and environmental excellence[189]. - The company maintains registrations in all 50 states, Washington D.C., Canada, and approximately 40 other countries, demonstrating its commitment to global safety[155].

Core Insights - TOMI Environmental Solutions, Inc. reported a 42% increase in revenue for Q1 2025 compared to the previous quarter, driven by strong demand for its product lines and recurring solution sales [2][3] - The company achieved a gross margin of 60.4%, slightly up from 60.2% in the prior year, and reduced its operating loss to $(754,000) from $(1,226,000) year-over-year [6] - Net loss decreased to $(256,000) or $(0.01) per share, compared to $(1,310,000) or $(0.07) per share in the same period last year [6] Financial Performance - Net sales for Q1 2025 were $1,577,000, up from $1,114,000 in Q1 2024, marking a significant year-over-year growth [6] - SteraMist product-based revenues increased to $1,000,000 from $743,000, reflecting a $257,000 rise due to heightened demand for various SteraMist solutions [6] - Service-based revenue also grew by 56%, reaching $577,000 compared to $371,000 in the prior year [6] Market Trends and Business Development - Domestic revenue surged by 80% to $1,192,000 from $662,000, attributed to increased demand for solutions and services [6] - The sales backlog as of March 31, 2025, was $1,225,000, an increase of $348,000 from December 31, 2024 [6] - A significant contract was secured for a SteraMist iHP Custom Engineered System at a university in Rhode Island, valued at approximately $450,000 [6] Strategic Partnerships and Expansion - TOMI announced the deployment of SteraMist iHP technology at NASA Johnson Space Center, indicating expansion into the aerospace sector [6] - An OEM partnership with Pharma Biotech System Components was established to enhance the SteraMist Integrated System [6] - The company is expanding into aquaculture with a new partner, Algafeed, further diversifying its market reach [7]

Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination solutions, utilizing its proprietary Binary Ionization Technology (BIT) platform [4] - The BIT solution employs a low percentage of hydrogen peroxide as its active ingredient, utilizing patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [4] - TOMI's products are applicable in various environments, including hospitals, biosafety labs, pharmaceutical facilities, schools, and commercial buildings [4] Financial Reporting - TOMI will report its first-quarter results for the period ending March 31, 2025, after the market closes on May 8, 2025 [1] - A conference call to discuss these results will be held at 4:30 p.m. ET on the same day [1] Participation Information - Participants can join the conference call by dialing (877) 545-0320 or (973) 528-0002 for international callers, using access code 616069 [2] - A replay of the teleconference will be available until May 22, 2025, with access codes provided for both domestic and international callers [3]

Financial Data and Key Metrics Changes - GAAP revenue increased to $7.739 million in 2024 from $7.355 million in 2023, driven by higher demand for mobile systems and IHP corporate service revenue [51] - Non-GAAP revenue was approximately $8 million, reflecting nearly a 6% increase over 2023 [52] - GAAP net loss was $4.477 million or $0.22 per share compared to a net loss of $3.403 million or $0.17 per share in the prior year [57] Business Line Data and Key Metrics Changes - Mobile equipment sales totaled approximately $3.8 million in 2024, reflecting a 23% growth compared to 2023 [54] - Service revenue generated around $2 million, a 23% increase from the previous year [54] - BIT solution sales reached approximately $900,000, marking a 9% growth [54] Market Data and Key Metrics Changes - The IHP corporate service division secured contracts extending through 2026, with a 42% increase in Q1 2025 compared to the same period last year [29] - Distribution arrangements resulted in 13 partners, leading to approximately $930,000 in sales for 2024 [27] - The company anticipates a $1 million pipeline with open proposals for 2025 in IHP corporate service deployment [65] Company Strategy and Development Direction - The company aims to expand the SteriMIST IHP brand globally and has established valuable partnerships in key markets [16] - Focus on enhancing sales infrastructure by establishing new distribution channels and recruiting independent representatives [59] - The company is committed to advancing healthcare initiatives and meeting regulatory requirements for medical devices [60] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, highlighting early successes in 2025 and a healthy pipeline [15] - The company is focused on returning to sustainable positive cash flow as soon as possible [50] - Management acknowledged challenges in the global food market but emphasized ongoing collaborations to address these issues [30] Other Important Information - The company has reduced R&D expenses by 41%, advertising and sales commissions by 17%, and consulting expenses by 20% in 2024 [48] - The company is actively pursuing new partnerships and expanding its market presence in regions like Panama, Nigeria, and Israel [64] - The SteriMIST Pro-Certified Program is expected to grow in membership by 2026, enhancing the utilization of SteriMIST products [72] Q&A Session Summary Question: Revenue guidance for the year and margin information - Management indicated that margins should remain around current levels and expressed confidence in the pipeline of projects for 2025 [85][89] Question: Impact of tariffs on the company - Management does not anticipate significant ramifications from the tariff situation at this time [100] Question: Adequacy of cash levels for upcoming opportunities - Management believes that with a planned raise and current accounts receivable, cash levels will be adequate to address opportunities [102] Question: Status of FDA rulings on 1% hydrogen peroxide for food applications - Management stated that it is difficult to predict the timeline for FDA rulings due to changes in regulatory agencies [110] Question: Modifications to SteriPak - Management confirmed that they are considering upgrades to surface units but are currently marketing the existing SteriPak [112]

Core Insights - TOMI Environmental Solutions, Inc. reported a 5% year-over-year increase in annual revenue for 2024, reaching $7.739 million compared to $7.355 million in 2023, while also expanding its customer base and product line [2][8] - The company experienced a GAAP net loss of $4.477 million for the year, compared to a loss of $3.403 million in the previous year, but noted improvements in non-GAAP financials, with a non-GAAP net loss of $2.050 million compared to $2.838 million in 2023 [3][4][8] - Preliminary Q1 2025 revenues are up 42% compared to Q1 2024, indicating a strong start to the year and a robust sales pipeline [2][16] Financial Performance - For the fourth quarter of 2024, net sales were $1.069 million, down from $1.528 million in Q4 2023, with a GAAP gross margin of -49.5% compared to 54.9% in the prior year [3][8] - Non-GAAP gross sales for Q4 2024 were $1.296 million, down from $1.656 million in Q4 2023, with a non-GAAP gross margin of 54.2% compared to 58.4% in the same period last year [4][8] - The total operating loss for the year was $4.105 million, compared to $3.349 million in 2023, while the non-GAAP operating loss improved to $1.678 million from $2.785 million [3][4][8] Business Highlights - SteraMist product-based revenues increased to $6.035 million in 2024 from $5.781 million in 2023, driven by higher demand for mobile and SIS units [8] - Service-based revenue also grew to $1.704 million in 2024 from $1.574 million in 2023, attributed to increased demand for iHP services [8] - International revenue grew by 33% in 2024, with new customers in Canada, South Africa, and India, and the company has established partnerships across various regions [8] Future Outlook - The company anticipates continued improvement in profitability throughout 2025, supported by high gross margins and a reduced expense structure [2][7] - Sales backlog increased to $1.232 million as of March 31, 2025, reflecting a 40% increase from December 31, 2024 [16] - The company is committed to nurturing partnerships with over 30 partners globally to strengthen the SteraMist brand [8]